VEGFR2/KDR/Flk-1 Antibody (91201) [Unconjugated]

Increased VEGF expression in the absence of Bim. In Panel A, VEGF levels of wild-type and Bim -/- astroglial cells were determined utilizing an ELISA as described in the Methods section. In Panel B, FACScan analysis was employed to assess VEGFR1 and VEGFR2 expression in wild-type and Bim -/- astroglial cells. The shaded histogram denotes staining in the presence of control IgG. Please note increased VEGF expression in the absence of Bim. No VEGFR2 expression was noted in retinal astroglial cells. (P***< 0.001; n = 6; student’s unpaired t-test (2-tailed) was utilized). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32365083), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB
• Clone: 91201
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

VEGFR2/KDR/Flk-1 Antibody (91201) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse VEGFR2
  Ala20-Glu762
  Accession # P35918
• Specificity: Detects mouse VEGFR2 in direct ELISAs and Western blots. Does not cross‑react with recombinant mouse (rm) VEGFR1 (Flt-1), recombinant human VEGFR2 (KDR), or rmVEGFR3 (Flt-4).
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat
• Gene: KDR
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR2/KDR/Flk-1 Antibody (91201) [Unconjugated]

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

Mouse VEGFR2 cDNA encodes a 1367 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 743 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 583 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
2. Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA. 95:548.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR2/KDR/Flk-1 Antibody (MAB443)(5)

Publications using MAB443

• J Falero-Per, N Sheibani, CM Sorenson Bim expression modulates the pro-inflammatory phenotype of retinal astroglial cells PLoS ONE, 2020-05-04;15(5):e0232779. 2020-05-04 [PMID: 32365083] (Flow Cytometry, Mouse)
• Nasim Jamali, Yong‐Seok Song, Christine M. Sorenson, Nader Sheibani 1,25(OH)2D3 regulates the proangiogenic activity of pericyte through VDR-mediated modulation of VEGF production and signaling of VEGF and PDGF receptors FASEB BioAdvances 8/10/2019 [PMID: 31396585]
• J Falero-Per, YS Song, Y Zhao, L Teixeira, CM Sorenson, N Sheibani Cyp1b1 expression impacts the angiogenic and inflammatory properties of liver sinusoidal endothelial cells PLoS ONE, 2018-10-29;13(10):e0206756. 2018-10-29 [PMID: 30372497] (Flow Cytometry, Mouse)
• Juliana Falero-Perez, SunYoung Park, Christine M. Sorenson, Nader Sheibani PEDF expression affects retinal endothelial cell proangiogenic properties through alterations in cell adhesive mechanisms American Journal of Physiology-Cell Physiology 10/1/2017 [PMID: 28747334]
• Funa NS, Kriz V, Zang G, Calounova G, Akerblom B, Mares J, Larsson E, Sun Y, Betsholtz C, Welsh M Dysfunctional microvasculature as a consequence of shb gene inactivation causes impaired tumor growth. Cancer Res., 2009-02-17;69(5):2141-8. 2009-02-17 [PMID: 19223532] (Western Blot, Mouse)

Bioinformatics

• Gene Symbol: KDR
• Uniprot:
  • P35918()